Live Feeds
● LIVE Updated 1h ago · 16 sources tracked

Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

Eli Lilly and the FDA provided one unnamed 79-year-old man access to the unapproved obesity drug retatrutide in April 2026. This access was granted through a compassionate use program. The identity of the patient has led to public speculation and White House denials.

RSS Source map (13)

What changed

New reports reveal the specific age of the patient and the date access was granted.

Live updates

  1. Eli Lilly Grants Experimental Weight Loss Drug to Single 79-Year-Old Patient

    Eli Lilly and the FDA provided one unnamed 79-year-old man access to the unapproved obesity drug retatrutide in April 2026. This access was granted through a compassionate use program. The identity of the patient has led to public speculation and White House denials.

    What's confirmed:

    • Eli Lilly and the FDA granted one 79-year-old man access to the unapproved drug retatrutide.
    • The drug was provided through a compassionate use program.
    • Access to the triple-agonist obesity drug was granted in April 2026.
    • The White House denied that the application for the drug was filed for Donald Trump.

    Still unconfirmed:

    • Donald Trump is the identity of the mystery 79-year-old patient.
    confidence 90%